Eisai Seeks Lunesta Approval In Japan After Phase III Data, But Disease Awareness Is A Challenge
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai announced Sept. 15 positive results from a Japanese Phase II/III efficacy study and a Phase III safety study for Lunesta (eszopiclone), giving the company adequate data to seek approval for the drug from Japan's Ministry of Health, Labor and Welfare in fiscal year 2010